ImCheck Therapeutics announced today that updated data from its ongoing Phase I/II study EVICTION will be presented in two poster sessions at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held in Houston, November 6-10, 2024. Both posters will provide updated results from the study assessing ICT01, a humanized anti-butyrophilin 3A (anti-BTN3A) monoclonal antibody that selectively activates γ9δ2 T cells, in combination with the checkpoint inhibitor pembrolizumab in patients with second-line or higher refractory metastatic melanoma and in patients with advanced urothelial cell carcinoma after failure with standard-of-care treatment.
Details of the poster presentations are:
Abstract number: 641
Presenter: Dr Stephane Champiat, University of Texas MD Anderson Cancer Center
Authors: Authors Stephane Champiat, Christophe Massard, Martin Wermke, Cecile Vicier, Emiliano Calvo, Elena Garralda, Evan Hall, Antoine Italiano, Benoit You, Hatem Soliman, Tatiana Hernandez, Christiane Jungels, Aude De Gassart, Emmanuel Valentin, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Daniel Olive, Stephan Braun, Johann De Bono
Date: Friday, Nov. 8, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
Abstract number: 692
Presenter: Dr Stephane Champiat, University of Texas MD Anderson Cancer Center
Authors: Stephane Champiat, Christophe Massard, Johann De Bono, Cecile Vicier, Emiliano Calvo, Evan Hall, Antoine Italiano, Benoit You, Hatem Soliman, Tatiana Hernandez, Christiane Jungels, Julien Vibert, Vladimir Galvao, Esma Saada, Aude De Gassart, Emmanuel Valentin, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Daniel Olive, Stephan Braun, Martin Wermke
Date: Saturday, Nov. 9, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
The SITC posters will be available on ImCheck’s corporate website after the poster sessions have been opened.